Kazuhiko Oshinomi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kazuhiko Oshinomi has a total of 115 co-authors. Here are the top co-authors by number of shared publications:
- Jun Morita
Department of Urology, Showa Medical University Hospital, Tokyo, Japan
7 shared publications - Yoshihiro Nakagami
Department of Urology Showa Medical University School of Medicine Tokyo Japan
7 shared publications Masakazu Nagata
Department of Urology Showa Medical University School of Medicine Tokyo Japan
6 shared publicationsTakashi Fukagai
Department of Urology Showa Medical University School of Medicine Tokyo Japan
5 shared publications- Takehiko Nakasato
Departments of Urology Showa University School of Medicine Tokyo Japan
5 shared publications - Takeshi Shichijo
Department of Urology, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-Ku, Tokyo, 142-8555, Japan
5 shared publications
Latest Publications
- Open Access
- 9 November 2026
- Published by Wiley in IJU Case Reports
- Vol. 9 (6)
Refractory Retroperitoneal Abscess Caused by Hypermucoviscous Klebsiella pneumoniae Requiring Open Surgical Drainage
Introduction: Klebsiella pneumoniae is broadly classified into classical and hypervirulent pathotypes, with the latter associated with invasive infections and hematogenous dissemination. Case Presentation: An 89‐year‐old woman presented with fever and fatigue. Imaging revealed a large retroperitoneal abscess. Klebsiella pneumoniae was isolated from both pus and urine cultures, and the string test was positive. The clinical response to nonsurgical treatment was poor; however, definitive infection control was achieved after open surgical drainage. Conclusion: This case highlights serial reassessment and kidney‐preserving open drainage for string test‐positive infection refractory to percutaneous source control.
- 9 November 2026
- Published by Wiley in IJU Case Reports
- Vol. 9 (6)
Open AccessRefractory Retroperitoneal Abscess Caused by Hypermucoviscous Klebsiella pneumoniae Requiring Open Surgical Drainage
Introduction: Klebsiella pneumoniae is broadly classified into classical and hypervirulent pathotypes, with the latter associated with invasive infections and hematogenous dissemination. Case Presentation: An 89‐year‐old woman presented with fever and fatigue. Imaging revealed a large retroperitoneal abscess. Klebsiella pneumoniae was isolated from both pus and urine cultures, and the string test was positive. The clinical response to nonsurgical treatment was poor; however, definitive infection control was achieved after open surgical drainage. Conclusion: This case highlights serial reassessment and kidney‐preserving open drainage for string test‐positive infection refractory to percutaneous source control.
- Open Access
Association of Prior Local Therapy with Outcomes Within Systemic Therapy Regimen Cohorts in Advanced Soft Tissue Sarcoma: A Retrospective Cohort Study
Background/Objectives: Evidence regarding associations between local therapy before an indexed systemic regimen and subsequent outcomes in advanced soft tissue sarcoma (STS) remains limited. We evaluated outcomes within four regimen-defined cohorts and explored associations with prior local-therapy history. Methods: This retrospective cohort included 75 patients with recurrent or metastatic STS who contributed 155 treatment episodes: doxorubicin (n = 44), trabectedin (n = 31), pazopanib (n = 42), and eribulin (n = 38). Progression-free survival (PFS) and overall survival (OS) were measured from initiation of the indexed regimen. Surgery, local ablative therapy, and radiation therapy were assessed separately and in combined categories. Post hoc analyses were restricted to leiomyosarcoma. Results: Median PFS was 3.4, 3.1, 5.1, and 3.9 months, respectively. PFS was longer with any local therapy and surgery and/or ablation in the trabectedin cohort (p = 0.0342 and p = 0.0111) and with surgery and/or ablation in the eribulin cohort (p = 0.0352). Longer indexed-regimen OS was observed in surgery-containing categories in the doxorubicin and eribulin cohorts. In selected multivariable models, local therapy was associated with OS in doxorubicin- and eribulin-treated episodes and with PFS in eribulin-treated episodes. Leiomyosarcoma-restricted analyses did not consistently reproduce the full-cohort findings. Conclusions: Prior local-therapy history was associated with PFS or OS in selected within-cohort analyses. The associations may reflect local-treatment effects, differences among selected patients, or both; however, the study cannot distinguish these contributions. No between-regimen differences were formally tested. These findings support individualized multidisciplinary assessment and external validation.
Open AccessAssociation of Prior Local Therapy with Outcomes Within Systemic Therapy Regimen Cohorts in Advanced Soft Tissue Sarcoma: A Retrospective Cohort Study
Background/Objectives: Evidence regarding associations between local therapy before an indexed systemic regimen and subsequent outcomes in advanced soft tissue sarcoma (STS) remains limited. We evaluated outcomes within four regimen-defined cohorts and explored associations with prior local-therapy history. Methods: This retrospective cohort included 75 patients with recurrent or metastatic STS who contributed 155 treatment episodes: doxorubicin (n = 44), trabectedin (n = 31), pazopanib (n = 42), and eribulin (n = 38). Progression-free survival (PFS) and overall survival (OS) were measured from initiation of the indexed regimen. Surgery, local ablative therapy, and radiation therapy were assessed separately and in combined categories. Post hoc analyses were restricted to leiomyosarcoma. Results: Median PFS was 3.4, 3.1, 5.1, and 3.9 months, respectively. PFS was longer with any local therapy and surgery and/or ablation in the trabectedin cohort (p = 0.0342 and p = 0.0111) and with surgery and/or ablation in the eribulin cohort (p = 0.0352). Longer indexed-regimen OS was observed in surgery-containing categories in the doxorubicin and eribulin cohorts. In selected multivariable models, local therapy was associated with OS in doxorubicin- and eribulin-treated episodes and with PFS in eribulin-treated episodes. Leiomyosarcoma-restricted analyses did not consistently reproduce the full-cohort findings. Conclusions: Prior local-therapy history was associated with PFS or OS in selected within-cohort analyses. The associations may reflect local-treatment effects, differences among selected patients, or both; however, the study cannot distinguish these contributions. No between-regimen differences were formally tested. These findings support individualized multidisciplinary assessment and external validation.
- Open Access
- 9 August 2026
- Published by Wiley in IJU Case Reports
- Vol. 9 (5)
Penile Metastasis From Castration‐Resistant Prostate Cancer: A Case Report
Introduction: Penile metastasis from prostate cancer—generally associated with a poor prognosis—is rare and underreported. We report one relevant case. Case Presentation: The patient was a 65‐year‐old male with metastatic hormone‐sensitive prostate cancer (prostate‐specific antigen [PSA]: 500 ng/mL) and lung, bone, and lymph node metastases. The patient received luteinizing hormone‐releasing hormone agonist monotherapy. The patient developed castration‐resistant prostate cancer and received androgen receptor signal inhibitor therapy and chemotherapy. As the disease progressed, a mass formed on his penis; biopsy revealed prostate cancer penile metastasis. The patient died 5 months later. Conclusion: Penile metastasis is rare and typically observed in advanced prostate cancer stages. Awareness may aid in early recognition, guide palliative management, and support patient counseling.
- 9 August 2026
- Published by Wiley in IJU Case Reports
- Vol. 9 (5)
Open AccessPenile Metastasis From Castration‐Resistant Prostate Cancer: A Case Report
Introduction: Penile metastasis from prostate cancer—generally associated with a poor prognosis—is rare and underreported. We report one relevant case. Case Presentation: The patient was a 65‐year‐old male with metastatic hormone‐sensitive prostate cancer (prostate‐specific antigen [PSA]: 500 ng/mL) and lung, bone, and lymph node metastases. The patient received luteinizing hormone‐releasing hormone agonist monotherapy. The patient developed castration‐resistant prostate cancer and received androgen receptor signal inhibitor therapy and chemotherapy. As the disease progressed, a mass formed on his penis; biopsy revealed prostate cancer penile metastasis. The patient died 5 months later. Conclusion: Penile metastasis is rare and typically observed in advanced prostate cancer stages. Awareness may aid in early recognition, guide palliative management, and support patient counseling.
- Open Access
- 27 May 2026
- Published by Wiley in IJU Case Reports
- Vol. 9 (4) , e70196
Neuroendocrine Transformation Without PSA Elevation in High‐Risk Metastatic Castration‐Sensitive Prostate Cancer Under Androgen Receptor Signaling Inhibition: A Case Report
Introduction: Neuroendocrine prostate cancer is a rare and highly aggressive variant of prostate cancer with a poor prognosis. We report a case in which metastatic castration‐sensitive prostate cancer directly transformed into neuroendocrine prostate cancer without a corresponding increase in prostate‐specific antigen. Case Presentation: An 86‐year‐old male with severe acute renal failure demonstrated a prostate‐specific antigen level of 306 ng/mL and a Gleason score of 4 + 5 on prostate biopsy. Imaging revealed lung, bone, and lymph node metastases, leading to a diagnosis of high‐risk metastatic castration‐sensitive prostate cancer. Abiraterone acetate was initiated immediately. Nineteen months later, multiple liver metastases were detected despite stable prostate‐specific antigen levels. The patient died 4 months later. Autopsy revealed widespread metastases, all histologically confirmed as neuroendocrine prostate cancer. Conclusion: Strong androgen receptor suppression in metastatic castration‐sensitive prostate cancer can lead to aggressive radiographic progression without prostate‐specific antigen elevation, underscoring the limitations of antigen‐based monitoring.
- 27 May 2026
- Published by Wiley in IJU Case Reports
- Vol. 9 (4) , e70196
Open AccessNeuroendocrine Transformation Without PSA Elevation in High‐Risk Metastatic Castration‐Sensitive Prostate Cancer Under Androgen Receptor Signaling Inhibition: A Case Report
Introduction: Neuroendocrine prostate cancer is a rare and highly aggressive variant of prostate cancer with a poor prognosis. We report a case in which metastatic castration‐sensitive prostate cancer directly transformed into neuroendocrine prostate cancer without a corresponding increase in prostate‐specific antigen. Case Presentation: An 86‐year‐old male with severe acute renal failure demonstrated a prostate‐specific antigen level of 306 ng/mL and a Gleason score of 4 + 5 on prostate biopsy. Imaging revealed lung, bone, and lymph node metastases, leading to a diagnosis of high‐risk metastatic castration‐sensitive prostate cancer. Abiraterone acetate was initiated immediately. Nineteen months later, multiple liver metastases were detected despite stable prostate‐specific antigen levels. The patient died 4 months later. Autopsy revealed widespread metastases, all histologically confirmed as neuroendocrine prostate cancer. Conclusion: Strong androgen receptor suppression in metastatic castration‐sensitive prostate cancer can lead to aggressive radiographic progression without prostate‐specific antigen elevation, underscoring the limitations of antigen‐based monitoring.
- Open Access
- 1 January 2026
- Published by Wiley in Advances in Urology
- Vol. 2026 (1) , 8111761
Neutropenia in Patients With Castration‐Resistant Prostate Cancer Treated Using Cabazitaxel and Prophylactic Administration of Pegfilgrastim
Background and Aims: Cabazitaxel has demonstrated survival benefits in patients with metastatic castration‐resistant prostate cancer (CRPC). However, Japanese patients are reported to experience higher rates of hematologic toxicity compared to their Caucasian counterparts. Although primary prophylaxis with pegfilgrastim is now routinely used in clinical practice, febrile neutropenia (FN) may still occur. In this study, we aimed to evaluate the real‐world safety of cabazitaxel with universal pegfilgrastim prophylaxis in Japanese patients with CRPC, particularly focusing on FN during the first treatment cycle. Methods: We retrospectively evaluated 86 patients with CRPC who received cabazitaxel at Showa Medical University–affiliated hospitals between 2015 and 2021. Cabazitaxel was administered every 3‐4 weeks at doses determined by the treating physicians, generally 20–25 mg/m 2 , with daily oral prednisolone. Pegfilgrastim was administered to all patients at least 24 h after cabazitaxel. Univariate analyses were performed to identify baseline factors associated with FN occurring during the first cycle of cabazitaxel. Exploratory logistic regression analysis was additionally performed for FN occurring during the entire treatment course. Results: Among the 86 patients, FN occurred in 12 patients (14.0%) during the entire treatment course, including 8 events (9.3%) during the first cycle. In univariate analyses, the only factor significantly associated with first‐cycle FN was a longer interval from CRPC diagnosis to cabazitaxel initiation (median, 1194.5 vs. 689 days, p = 0.0094). A similar tendency was observed when FN occurrence during the entire treatment course was analyzed. In exploratory logistic regression analysis for FN during the entire treatment course, the same factor showed a consistent trend toward association with FN development. Conclusion: Despite universal pegfilgrastim prophylaxis, approximately 10% of Japanese patients developed FN during the first cycle of cabazitaxel therapy. A longer interval from CRPC diagnosis to cabazitaxel initiation showed a consistent trend toward association with FN risk in Japanese patients across analyses. These findings provide real‐world safety data and highlight the importance of careful hematologic monitoring, particularly in patients treated later in the CRPC disease course.
- 1 January 2026
- Published by Wiley in Advances in Urology
- Vol. 2026 (1) , 8111761
Open AccessNeutropenia in Patients With Castration‐Resistant Prostate Cancer Treated Using Cabazitaxel and Prophylactic Administration of Pegfilgrastim
Background and Aims: Cabazitaxel has demonstrated survival benefits in patients with metastatic castration‐resistant prostate cancer (CRPC). However, Japanese patients are reported to experience higher rates of hematologic toxicity compared to their Caucasian counterparts. Although primary prophylaxis with pegfilgrastim is now routinely used in clinical practice, febrile neutropenia (FN) may still occur. In this study, we aimed to evaluate the real‐world safety of cabazitaxel with universal pegfilgrastim prophylaxis in Japanese patients with CRPC, particularly focusing on FN during the first treatment cycle. Methods: We retrospectively evaluated 86 patients with CRPC who received cabazitaxel at Showa Medical University–affiliated hospitals between 2015 and 2021. Cabazitaxel was administered every 3‐4 weeks at doses determined by the treating physicians, generally 20–25 mg/m 2 , with daily oral prednisolone. Pegfilgrastim was administered to all patients at least 24 h after cabazitaxel. Univariate analyses were performed to identify baseline factors associated with FN occurring during the first cycle of cabazitaxel. Exploratory logistic regression analysis was additionally performed for FN occurring during the entire treatment course. Results: Among the 86 patients, FN occurred in 12 patients (14.0%) during the entire treatment course, including 8 events (9.3%) during the first cycle. In univariate analyses, the only factor significantly associated with first‐cycle FN was a longer interval from CRPC diagnosis to cabazitaxel initiation (median, 1194.5 vs. 689 days, p = 0.0094). A similar tendency was observed when FN occurrence during the entire treatment course was analyzed. In exploratory logistic regression analysis for FN during the entire treatment course, the same factor showed a consistent trend toward association with FN development. Conclusion: Despite universal pegfilgrastim prophylaxis, approximately 10% of Japanese patients developed FN during the first cycle of cabazitaxel therapy. A longer interval from CRPC diagnosis to cabazitaxel initiation showed a consistent trend toward association with FN risk in Japanese patients across analyses. These findings provide real‐world safety data and highlight the importance of careful hematologic monitoring, particularly in patients treated later in the CRPC disease course.
- Open Access
- 11 October 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (10) , 567
Predictive Factors and Clinical Impact of Radioactive Seed Migration After Prostate Brachytherapy: A Retrospective Study
Radioactive seed migration after low-dose-rate brachytherapy (LDR-BT) for prostate cancer is a known phenomenon; however, its clinical impact remains unclear. We retrospectively analyzed 611 patients treated with LDR-BT using loose iodine-125 seeds. Post-treatment imaging was used to assess seed migration. Treatment efficacy was evaluated using post-plan dosimetry (V100 and D90) and biochemical recurrence-free survival (bRFS). Seed migration was observed in 150 patients (24.5%) within 1–3 months post-treatment, involving a total of 210 seeds. Migration sites included lungs, vasculature, and seminal vesicles. Hematogenous migration was significantly associated with higher seed counts. Seminal vesicle migration was linked to increased needle usage and absence of neoadjuvant hormone therapy. No significant differences were observed in V100, D90, or bRFS between patients with or without seed migration. However, migration of ≥3 seeds correlated with significantly lower V100 and with a trend toward decreased bRFS. Limited seed migration appears to have minimal clinical impact. However, ≥3 migrated seeds may reduce dosimetric quality and affect treatment efficacy. Risk factors include larger prostate volume as well as higher seed and needle counts. Improved planning and using linked seeds may reduce migration and improve outcomes in LDR-BT for prostate cancer.
- 11 October 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (10) , 567
Open AccessPredictive Factors and Clinical Impact of Radioactive Seed Migration After Prostate Brachytherapy: A Retrospective Study
Radioactive seed migration after low-dose-rate brachytherapy (LDR-BT) for prostate cancer is a known phenomenon; however, its clinical impact remains unclear. We retrospectively analyzed 611 patients treated with LDR-BT using loose iodine-125 seeds. Post-treatment imaging was used to assess seed migration. Treatment efficacy was evaluated using post-plan dosimetry (V100 and D90) and biochemical recurrence-free survival (bRFS). Seed migration was observed in 150 patients (24.5%) within 1–3 months post-treatment, involving a total of 210 seeds. Migration sites included lungs, vasculature, and seminal vesicles. Hematogenous migration was significantly associated with higher seed counts. Seminal vesicle migration was linked to increased needle usage and absence of neoadjuvant hormone therapy. No significant differences were observed in V100, D90, or bRFS between patients with or without seed migration. However, migration of ≥3 seeds correlated with significantly lower V100 and with a trend toward decreased bRFS. Limited seed migration appears to have minimal clinical impact. However, ≥3 migrated seeds may reduce dosimetric quality and affect treatment efficacy. Risk factors include larger prostate volume as well as higher seed and needle counts. Improved planning and using linked seeds may reduce migration and improve outcomes in LDR-BT for prostate cancer.
- Open Access
- 29 August 2025
- Published by Elsevier in Prostate International
- Vol. 13 (4) , 271-275
Utility of the prostate health index density for detecting clinically significant prostate cancer in patients with negative magnetic resonance imaging findings
- 29 August 2025
- Published by Elsevier in Prostate International
- Vol. 13 (4) , 271-275
Open AccessUtility of the prostate health index density for detecting clinically significant prostate cancer in patients with negative magnetic resonance imaging findings
- Open Access
- 3 May 2025
- Published by International Institute of Anticancer Research in Cancer Diagnosis & Prognosis
- Vol. 5 (3) , 313-318
Preoperative Predictive Factors for Seminal Vesicle Invasion (pT3b) in Robotic‐assisted Radical Prostatectomy
Background/Aim: Robot-assisted radical prostatectomy (RARP) outcomes improve with surgical experience, but preoperative prediction of disease stage is crucial to avoid unexpected T stage upgrades, such as pT3b. This study aimed to identify preoperative predictive factors for pT3b (seminal vesicle invasion) following RARP. Patients and Methods: Out of 299 RARP performed between 2013 and 2020, 246 cases without preoperative hormone therapy were included. Of these, 19 cases (7.7%) were pT3b. T classification was performed using magnetic resonance imaging (MRI), and 12-site prostate biopsies were conducted. Cox proportional hazards, logistic regression analysis, and Kaplan-Meier analyses were used. Results: The 3-year prostate specific antigen (PSA) recurrence-free survival rate was 87% but significantly lower at 70% for pT3b cases. Multivariate logistic regression analysis identified the International Society of Urological Pathology (ISUP) grade group at biopsy as the only significant preoperative predictor of pT3b. Conclusion: pT3b is associated with increased postoperative biochemical recurrence risk, and ISUP grade group at biopsy serves as a significant preoperative predictive factor for pT3b.
- 3 May 2025
- Published by International Institute of Anticancer Research in Cancer Diagnosis & Prognosis
- Vol. 5 (3) , 313-318
Open AccessPreoperative Predictive Factors for Seminal Vesicle Invasion (pT3b) in Robotic‐assisted Radical Prostatectomy
Background/Aim: Robot-assisted radical prostatectomy (RARP) outcomes improve with surgical experience, but preoperative prediction of disease stage is crucial to avoid unexpected T stage upgrades, such as pT3b. This study aimed to identify preoperative predictive factors for pT3b (seminal vesicle invasion) following RARP. Patients and Methods: Out of 299 RARP performed between 2013 and 2020, 246 cases without preoperative hormone therapy were included. Of these, 19 cases (7.7%) were pT3b. T classification was performed using magnetic resonance imaging (MRI), and 12-site prostate biopsies were conducted. Cox proportional hazards, logistic regression analysis, and Kaplan-Meier analyses were used. Results: The 3-year prostate specific antigen (PSA) recurrence-free survival rate was 87% but significantly lower at 70% for pT3b cases. Multivariate logistic regression analysis identified the International Society of Urological Pathology (ISUP) grade group at biopsy as the only significant preoperative predictor of pT3b. Conclusion: pT3b is associated with increased postoperative biochemical recurrence risk, and ISUP grade group at biopsy serves as a significant preoperative predictive factor for pT3b.
- Open Access
- 3 January 2025
- Published by International Institute of Anticancer Research in Cancer Diagnosis & Prognosis
- Vol. 5 (1) , 56-61
Current Status of Sequential Treatment for Castration-resistant Prostate Cancer: A Retrospective Analysis
Background/Aim: Although multiple treatments are available for metastatic castration-resistant prostate cancer, data to determine the optimal treatment sequence are limited. This study aimed to investigate the current status of drug therapy for castration-resistant prostate cancer and clarify the sequential treatment in actual clinical practice. Patients and Methods: This retrospective study included 425 patients diagnosed with castration-resistant prostate cancer at Showa University Hospital and affiliated hospitals between January 2014 and December 2021, who were treated with any of the following four drugs: novel androgen receptor signal inhibitors (abiraterone acetate and enzalutamide) and anticancer drugs (docetaxel and cabazitaxel). We investigated the actual treatment choices for castration-resistant prostate cancer, focusing on the order of administration of the four drugs. This analysis was visualized using a Sankey diagram. Results: Regarding the number of drugs administered, most patients received one type of drug, with androgen receptor signal inhibitors being the most commonly administered (total, 179; enzalutamide, 139 and abiraterone acetate, 40). Enzalutamide was the most frequently selected first-line drug (58.4%). The most common sequence for second-line treatment was androgen receptor signal inhibitor-androgen receptor signal inhibitor (n=96), followed by androgen receptor signal inhibitor-docetaxel (n=85), docetaxel-androgen receptor signal inhibitor (n=59), and docetaxel-cabazitaxel (n=6). Conclusion: Androgen receptor signal inhibitors is the most commonly used drug category for first-line treatment of castration-resistant prostate cancer, with enzalutamide being the most commonly used drug. Further investigations are required regarding patient background and prognosis.
- 3 January 2025
- Published by International Institute of Anticancer Research in Cancer Diagnosis & Prognosis
- Vol. 5 (1) , 56-61
Open AccessCurrent Status of Sequential Treatment for Castration-resistant Prostate Cancer: A Retrospective Analysis
Background/Aim: Although multiple treatments are available for metastatic castration-resistant prostate cancer, data to determine the optimal treatment sequence are limited. This study aimed to investigate the current status of drug therapy for castration-resistant prostate cancer and clarify the sequential treatment in actual clinical practice. Patients and Methods: This retrospective study included 425 patients diagnosed with castration-resistant prostate cancer at Showa University Hospital and affiliated hospitals between January 2014 and December 2021, who were treated with any of the following four drugs: novel androgen receptor signal inhibitors (abiraterone acetate and enzalutamide) and anticancer drugs (docetaxel and cabazitaxel). We investigated the actual treatment choices for castration-resistant prostate cancer, focusing on the order of administration of the four drugs. This analysis was visualized using a Sankey diagram. Results: Regarding the number of drugs administered, most patients received one type of drug, with androgen receptor signal inhibitors being the most commonly administered (total, 179; enzalutamide, 139 and abiraterone acetate, 40). Enzalutamide was the most frequently selected first-line drug (58.4%). The most common sequence for second-line treatment was androgen receptor signal inhibitor-androgen receptor signal inhibitor (n=96), followed by androgen receptor signal inhibitor-docetaxel (n=85), docetaxel-androgen receptor signal inhibitor (n=59), and docetaxel-cabazitaxel (n=6). Conclusion: Androgen receptor signal inhibitors is the most commonly used drug category for first-line treatment of castration-resistant prostate cancer, with enzalutamide being the most commonly used drug. Further investigations are required regarding patient background and prognosis.
- Open Access
- 1 April 2021
- Published by Oxford University Press (OUP) in Journal of Surgical Case Reports
- Vol. 2021 (4) , rjab092
Lung adenocarcinoma diagnosed incidentally after renal biopsy for suspected right renal cancer
We present a case of lung adenocarcinoma metastasizing to the right clear cell renal cell carcinoma diagnosed by computed tomography (CT)-guided renal biopsy and immunohistochemistry. A 72-year-old male patient had right lower abdominal pain for 3 days, followed by right loin pain for 10 days. On CT scan, renal cell cancer was suspected with multiple metastases. Renal cell cancer with metastatic lung adenocarcinoma was diagnosed on CT-guided renal biopsy with positive immunohistochemical markers. The patient, unfortunately, expired after few days of diagnosis. Tumor-to-tumor metastasis is an unusual disease, and its tumors are aggressive. A definite diagnosis of tumor-to-tumor metastasis is a clinical challenge. Immunohistochemistry helped us in the diagnosis without the primary lesion biopsy.
- 1 April 2021
- Published by Oxford University Press (OUP) in Journal of Surgical Case Reports
- Vol. 2021 (4) , rjab092
Open AccessLung adenocarcinoma diagnosed incidentally after renal biopsy for suspected right renal cancer
We present a case of lung adenocarcinoma metastasizing to the right clear cell renal cell carcinoma diagnosed by computed tomography (CT)-guided renal biopsy and immunohistochemistry. A 72-year-old male patient had right lower abdominal pain for 3 days, followed by right loin pain for 10 days. On CT scan, renal cell cancer was suspected with multiple metastases. Renal cell cancer with metastatic lung adenocarcinoma was diagnosed on CT-guided renal biopsy with positive immunohistochemical markers. The patient, unfortunately, expired after few days of diagnosis. Tumor-to-tumor metastasis is an unusual disease, and its tumors are aggressive. A definite diagnosis of tumor-to-tumor metastasis is a clinical challenge. Immunohistochemistry helped us in the diagnosis without the primary lesion biopsy.